on RHÖN-KLINIKUM AG (ETR:RHK)
RHÖN-KLINIKUM AG Reports Steady Progress in 2025
RHÖN-KLINIKUM AG has achieved stable financial outcomes for 2025, meeting its targets despite challenges in health policy and economics. The company enhanced its revenue by 6.8%, reaching EUR 1,704.7 million, due to a 2.8% rise in treated patients to over 938,000. However, consolidated profit fell to EUR 36.3 million because of increased depreciation and interest rate reductions. The firm plans to distribute a EUR 0.20 dividend per share.
The company invested in new medical technologies and expanded care offerings across locations. Notable enhancements include advanced cardiac technology in Marburg and a cancer radiotherapy system in Bad Berka. For 2026, RHÖN-KLINIKUM AG forecasts revenues around EUR 1.7 billion, with potential variances due to regulatory and economic uncertainties.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all RHÖN-KLINIKUM AG news